• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 31, 2024
Distillery Therapeutics

Epitope-specific, nanobody-based CAR T cells targeting B7-H3 for solid tumors

Read More
BioCentury | Feb 28, 2023
Data Byte

AZ enters crowded CLDN18.2 clinical race via Keymed deal

At least 28 therapies targeting CLDN18.2 have started clinical trials for cancer
Read More
BioCentury | Jan 27, 2023
Finance

Jan. 26 Quick Takes: Grey Wolf bringing neoantigen-booster to the clinic with $49M B round

Plus: Keytruda approved for adjuvant NSCLC and updates for AZ’s Evusheld, BMS’s Breyanzi, Magenta, Theonys and more
Read More
BioCentury | Mar 19, 2022
Discovery & Translation

A computationally designed IL-2; plus Adimab/Mapp, Kahr and more

BioCentury’s roundup of translational news
Read More
BioCentury | Dec 22, 2021
Product Development

PD-1’s new narrative – a bonanza of innovation

Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
Read More
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Chengdu-based Clover is targeting cancer and infectious disease pathways that depend on trimer formation
Read More
BioCentury | Mar 12, 2020
Product Development

With initial PKU trial ‘uninterpretable,’ Rubius turns to cancer, autoimmune diseases

Read More
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

Read More
BioCentury | Jan 8, 2020
Financial News

With $69M D round, Adagene looks to Phase II for solid, blood cancers

Read More
BioCentury | Nov 15, 2019
Preclinical News

Nov. 14 Preclinical Quick Takes: Gut microbe-targeting phage for alcoholic liver disease; plus Cellectis, Biomica, University of Michigan and Rubius

Read More
Items per page:
1 - 10 of 23